Min Jung Kim

Title: Min Jung Kim - Innovator in Hemophilia Treatment

Introduction

Min Jung Kim is a prominent inventor based in Yongin-si, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of hemophilia. His innovative work focuses on developing highly efficient antibody compositions that can improve patient outcomes.

Latest Patents

Min Jung Kim holds a patent for a "Highly efficient anti-TFPI antibody composition." This patent describes a pharmaceutical composition that includes an anti-TFPI antibody specifically designed for treating hemophilia. The composition is notable for having a content of HCP in the drug substance that is less than 10.0 ng/mg, and the content of LPA in the drug substance or drug product is less than 1.0 ng/mg. This innovative approach minimizes the generation of anti-TFPI antibody polymers, making it effective for treating patients with antibody-induced hemophilia and preventing blood coagulation diseases.

Career Highlights

Throughout his career, Min Jung Kim has been associated with The Green Cross Corporation, where he has been instrumental in advancing research and development in the pharmaceutical sector. His work has not only contributed to the company's portfolio but has also had a broader impact on the treatment of hemophilia.

Collaborations

Min Jung Kim has collaborated with notable colleagues, including Geun Hye Yeo and Haeng Eun Song. These partnerships have fostered a collaborative environment that enhances innovation and research in their field.

Conclusion

Min Jung Kim's contributions to the development of anti-TFPI antibody compositions represent a significant advancement in hemophilia treatment. His innovative approach and dedication to research continue to pave the way for improved therapeutic options for patients.